Vertex Pharmaceuticals Inc. share price logo

Vertex Pharmaceuticals Inc.

NASDAQ: VRTX

Large Cap

$484.83

+6.12

(+1.28%)

as on

Vertex Pharmaceuticals Inc. Stock Performance

as on August 6, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $479.02
    $491.20
    downward going graph

    1.20%

    Downside

    1.31%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $362.50
    $533.67
    downward going graph

    25.23%

    Downside

    10.07%

    Upside

    downward going graph

Vertex Pharmaceuticals Inc. share price movements today

Previous Close
$478.70
Open
$487.52
Volume
592.7K
Day's Low - High
$479.02 - $491.20
52 Week Low - High
$362.50 - $533.67

Vertex Pharmaceuticals Inc. Historical Returns

1 Month Return
-8.45 %
3 Month Return
+ 13.37 %
1 Year Return
+ 25.72 %
3 Year Return
+ 42.4 %
5 Year Return
+ 141.61 %

Vertex Pharmaceuticals Inc. Stock Fundamentals & Key Indicators

Check Vertex Pharmaceuticals Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$121.3B

EPS (TTM)

18.6737

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.08%

PE Ratio (TTM)

27.93

Industry PE ratio

3.7915384615384613

PEG Ratio

1.6174

EBITDA

5.1B

Revenue (TTM)

12.6B

Profit Margin

35.00%

Return On Equity TTM

23.54%

Vertex Pharmaceuticals Inc. Stock Valuation

Track how Vertex Pharmaceuticals Inc. P/E has moved over time to understand its valuation trends.

Vertex Pharmaceuticals Inc. in the last 5 years

  • Overview

  • Trends

Lowest (14.94x)

December 31, 2021

Industry (3.79x)

August 6, 2026

Today (27.93x)

August 6, 2026

Highest (27.20x)

June 30, 2025

LowHigh

Today’s Price to Earnings Ratio: 27.93x

Vertex Pharmaceuticals Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Vertex Pharmaceuticals Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$121.3B141.61%27.9335.00%NA
Revolution Medicines Inc. image
Revolution Medicines Inc.
BUY$41.1B605.15%NA0.00%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$78.3B25.82%18.827.87%0.48%

Stock Returns calculator for Vertex Pharmaceuticals Inc. Stock including INR - Dollar returns

The Vertex Pharmaceuticals Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Vertex Pharmaceuticals Inc. investment value today

Current value as on today

₹1,36,268

Returns

₹36,268

(+36.27%)

Returns from Vertex Pharmaceuticals Inc. Stock

₹25,718 (+25.72%)

Dollar Impact

₹10,550 (+10.55%)

Analyst Recommendation on Vertex Pharmaceuticals Inc. Stock

Based on 38 analysts

BUY

68.42%

Buy

26.32%

Hold

5.26%

Sell

Based on 38 analysts, 68.42% of analysts recommend a 'BUY' rating for Vertex Pharmaceuticals Inc.. Average target price of $558.32

Vertex Pharmaceuticals Inc. Share Price Target

Get share price movements and forecasts by analysts on Vertex Pharmaceuticals Inc..

What analysts predicted

13.16%UPSIDE

Target Price

$558.32

Current Price

$484.83

Analyzed by

38 Analysts

Target

$558.32

Vertex Pharmaceuticals Inc. target price $558.32, a slight upside of 13.16% compared to current price of $484.83. According to 38 analysts rating.

Indian Investors' Interest in Vertex Pharmaceuticals Inc. Stock

Investment in Vertex Pharmaceuticals Inc. Shares on INDmoney has grown by 36.11% in the last 30 days, indicating increased investment activity.

Time period: to

Change:36.11% versus previous 30 day period

Search interest for Vertex Pharmaceuticals Inc. Stock has increased by 29% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:29% versus previous 30 day period

Vertex Pharmaceuticals Inc. Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
2,687
2,645
2,771
2,912
2,770
2,964
3,076
3,227
2,986
3,333
Gross Profit
2,344
2,273
2,379
2,488
2,407
2,557
2,661
2,761
2,594
2,844
Operating Income
1,139
-3,514
1,116
1,026
630
1,151
1,186
1,300
1,138
1,246
EBITDA
1,343
-3,327
1,284
1,184
781
1,338
1,356
1,387
1,308
1,335
Interest Expense
10
9
7
2
3
3
3
3
-
-
Depreciation
53
54
53
46
48
51
54
55
55
-
Income Before Tax
1,279
-3,391
1,224
1,136
730
1,283
1,298
1,331
1,252
1,391
Income Tax Expense
179
202
178
223
84
250
215
139
221
292
Net Income
1,099
-3,593
1,045
913
646
1,032
1,082
1,191
1,031
1,099
Net Profit Margin
40.92%
-135.83%
37.71%
31.35%
23.33%
34.84%
35.20%
36.91%
34.53%
32.99%

Vertex Pharmaceuticals Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1,702
2,488
3,047
4,162
6,205
7,574
8,930
9,869
11,020
12,074
Gross Profit
1,491
2,213
2,638
3,615
5,469
6,670
7,850
8,607
9,489
10,267
Operating Income
9
123
635
1,197
2,856
2,782
4,307
3,832
-232
4,760
EBITDA
75
103
706
1,560
3,284
2,917
4,435
4,605
486
4,863
Interest Expense
81
69
34
58
58
61
54
44
30
13
Depreciation
-
61
72
106
109
125
148
181
207
209
Income Before Tax
-67
-15
600
1,394
3,116
2,730
4,232
4,379
248
4,643
Income Tax Expense
16
-107
-1,486
218
405
388
910
760
784
690
Net Income
-112
263
2,096
1,176
2,711
2,342
3,322
3,619
-535
3,953
Net Profit Margin
-6.58%
10.59%
68.80%
28.27%
43.70%
30.92%
37.20%
36.68%
-4.86%
32.74%

Vertex Pharmaceuticals Inc. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
1,099
-3,593
1,045
913
646
1,032
1,082
1,191
1,031
Operating Cash Flow
1,306
-3,753
1,369
584
818
1,073
1,241
498
1,428
Investing Cash Flow
-2,136
-463
-348
-821
-55
-484
-117
-288
-431
Financing Cash Flow
-357
-358
-387
-391
-680
-349
-1,154
-77
-538
Change in Cash
-1,202
-4,578
657
-675
113
296
-34
140
417

Vertex Pharmaceuticals Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
91
2,087
1,176
2,711
2,342
3,322
3,619
-535
3,953
Operating Cash Flow
844
1,270
1,569
3,253
2,643
4,129
3,537
-492
3,631
Investing Cash Flow
-437
-202
-1,235
99
-340
-321
-3,141
-3,770
-945
Financing Cash Flow
68
-71
126
-505
-1,478
-67
-562
-1,494
-2,261
Change in Cash
481
990
462
2,868
811
3,711
-139
-5,800
515

Mutual Funds that own Vertex Pharmaceuticals Inc. Stock

Check out the Mutual Funds with significant holdings in Vertex Pharmaceuticals Inc..

Global Institutional Holdings in Vertex Pharmaceuticals Inc.

Funds
Holdings
Jennison Associates LLC
1.08%
Capital World Investors
10%
Vanguard Capital Management, LLC
6.51%
State Street Corp
4.62%
Vanguard Portfolio Management, LLC
2.03%
See all

Vertex Pharmaceuticals Inc. News & Key Events

  • img

    Today's Timeline - 29 July

    Wed, 06:45 PM

    -

    Vertex expected to report Q2 earnings of $4.85 per share, with revenue forecasted at $3.23 billion.

    Wed, 09:38 PM

    -

    Vertex Pharmaceuticals shows 31.4% undervaluation based on DCF analysis, despite strong historical performance.

    Thu, 00:38 AM

    -

    Vertex collaborates with AbCellera to develop T cell engagers, enhancing pipeline diversification and growth potential.

Insights on Vertex Pharmaceuticals Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Vertex Pharmaceuticals has shown positive profit trends over the past two quarters. The company's net profit increased from $1.03 billion to $1.09 billion, reflecting an average growth of 6.2% each quarter.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Vertex Pharmaceuticals has shown positive revenue growth over the past two quarters. Revenue increased from $2.98 billion to $3.33 billion, reflecting an average growth of 10.4% per quarter.

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Revolution Medicines, Inc. Common Stock has given 438.0% return, outperforming this stock by 412.3%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Revolution Medicines, Inc. Common Stock has given 532.2% return, outperforming this stock by 489.8%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 1 month, VRTX stock has moved down by -8.5%

About Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
OrganisationVertex Pharmaceuticals Inc.
Headquarters50 Northern Avenue, Boston, MA, United States, 02210
IndustryBiotechnology
CEODr. Reshma Kewalramani FASN, M.D.
E-voting on sharesClick here to vote

Key Management of Vertex Pharmaceuticals Inc.

Name

Title

Ms. Kristen C. Ambrose CPA

Senior VP & Chief Accounting Officer

Dr. Mark Bunnage D.Phil

Executive VP & Chief Scientific Officer

Dr. Jeffrey Marc Leiden M.D., Ph.D.

Executive Chairman

Dr. Reshma Kewalramani FASN, M.D.

CEO, President & Director

Dr. Ourania Tatsis Ph.D.

Executive VP and Chief Regulatory & Quality Officer

Dr. Carmen Bozic M.D.

Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer

Ms. Susie Lisa C.F.A.

Senior Vice President of Investor Relations

Ms. Joy Liu J.D.

EVP, Chief Legal Officer & Corporate Secretary

Mr. Charles F. Wagner Jr.

Executive VP, COO & CFO

Mr. Amit K. Sachdev J.D.

Executive VP & Chief Patient and External Affairs Officer

FAQs

What is Vertex Pharmaceuticals Inc. share price today?

Vertex Pharmaceuticals Inc. share price today is $484.83 as on at the close of the market. Vertex Pharmaceuticals Inc. share today touched a day high of $491.20 and a low of $479.02.

What is the 52 week high and 52 week low for Vertex Pharmaceuticals Inc. share?

Vertex Pharmaceuticals Inc. share touched a 52 week high of $533.67 on and a 52 week low of $362.50 on . Vertex Pharmaceuticals Inc. stock price today i.e. is closed at $484.83,which is 9.15% down from its 52 week high and 33.75% up from its 52 week low.

What is Vertex Pharmaceuticals Inc.'s market capitalisation today?

Vertex Pharmaceuticals Inc. market capitalisation is $0.12T as on .

How to invest in Vertex Pharmaceuticals Inc. Stock (VRTX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Vertex Pharmaceuticals Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Vertex Pharmaceuticals Inc. Shares that will get you 0.0031 shares as per Vertex Pharmaceuticals Inc. share price of $484.83 per share as on August 6, 2026 at 8:46 am IST.

What is the minimum amount required to buy Vertex Pharmaceuticals Inc. Stock (VRTX) from India?

Indian investors can start investing in Vertex Pharmaceuticals Inc. (VRTX) shares with as little as ₹95.2 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹952.00 in Vertex Pharmaceuticals Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Vertex Pharmaceuticals Inc. share’s latest price of $484.83 as on August 6, 2026 at 8:46 am IST, you will get 0.0206 shares of Vertex Pharmaceuticals Inc.. Learn more about fractional shares .

What are the returns that Vertex Pharmaceuticals Inc. has given to Indian investors in the last 5 years?

Vertex Pharmaceuticals Inc. stock has given 141.61% share price returns and 28.66% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?